Adaptive Biotechnologies Corp
ADPT15.760USD
-0.200-1.25%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
2.40BMarket Cap
LossP/E TTM
More Details of Adaptive Biotechnologies Corp Company
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Adaptive Biotechnologies Corp Info
Ticker SymbolADPT
Company nameAdaptive Biotechnologies Corp
IPO dateJun 27, 2019
CEORobins (Chad M)
Number of employees619
Security typeOrdinary Share
Fiscal year-endJun 27
Address1165 Eastlake Ave E
CitySEATTLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98109
Phone12066590067
Websitehttps://www.adaptivebiotech.com
Ticker SymbolADPT
IPO dateJun 27, 2019
CEORobins (Chad M)
Company Executives of Adaptive Biotechnologies Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.72M
-124998.00%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+93948.00%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
315.98K
--
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+15934.00%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+17045.00%
Mr. Kyle Piskel
Mr. Kyle Piskel
Chief Financial Officer
Chief Financial Officer
47.39K
-1929.00%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Director
Independent Director
31.33K
-22968.00%
Dr. Harlan S. Robins, Ph.D.
Dr. Harlan S. Robins, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Ms. Julie Rubinstein
Ms. Julie Rubinstein
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
--
-95932.00%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.72M
-124998.00%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+93948.00%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
315.98K
--
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+15934.00%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+17045.00%
Mr. Kyle Piskel
Mr. Kyle Piskel
Chief Financial Officer
Chief Financial Officer
47.39K
-1929.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
MRD revenue
56.79M
60.43%
Immune meidicine revenue
37.19M
39.57%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
MRD revenue
56.79M
60.43%
Immune meidicine revenue
37.19M
39.57%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Viking Global Investors LP
19.65%
The Vanguard Group, Inc.
7.37%
BlackRock Institutional Trust Company, N.A.
7.15%
Columbia Threadneedle Investments (US)
3.79%
Amova Asset Management Co., Ltd.
2.39%
Other
59.66%
Shareholders
Shareholders
Proportion
Viking Global Investors LP
19.65%
The Vanguard Group, Inc.
7.37%
BlackRock Institutional Trust Company, N.A.
7.15%
Columbia Threadneedle Investments (US)
3.79%
Amova Asset Management Co., Ltd.
2.39%
Other
59.66%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
49.22%
Investment Advisor
37.14%
Hedge Fund
7.29%
Individual Investor
2.36%
Research Firm
1.98%
Venture Capital
0.61%
Bank and Trust
0.29%
Pension Fund
0.29%
Insurance Company
0.16%
Other
0.66%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
513
148.08M
97.00%
-11.13M
2025Q3
525
148.26M
105.04%
-2.06M
2025Q2
504
149.94M
107.92%
-3.26M
2025Q1
483
152.16M
101.42%
-1.92M
2024Q4
465
141.42M
106.29%
+2.24M
2024Q3
461
140.16M
113.07%
-6.52M
2024Q2
469
146.66M
109.65%
-1.77M
2024Q1
489
141.83M
104.71%
-12.49M
2023Q4
514
142.64M
110.01%
+3.31M
2023Q3
513
139.83M
105.19%
+4.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Viking Global Investors LP
29.99M
19.65%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
11.25M
7.37%
-4.03K
-0.04%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
10.91M
7.15%
-154.89K
-1.40%
Sep 30, 2025
Columbia Threadneedle Investments (US)
5.78M
3.79%
+3.43M
+145.35%
Sep 30, 2025
Amova Asset Management Co., Ltd.
3.65M
2.39%
-649.04K
-15.10%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.40M
2.23%
+185.86K
+5.78%
Sep 30, 2025
ARK Investment Management LLC
3.17M
2.07%
-850.85K
-21.18%
Sep 30, 2025
Aristotle Atlantic Partners, LLC
3.13M
2.05%
+247.40K
+8.59%
Sep 30, 2025
State Street Investment Management (US)
3.08M
2.02%
+52.11K
+1.72%
Sep 30, 2025
Driehaus Capital Management, LLC
3.02M
1.98%
+596.35K
+24.61%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Franklin Genomic Advancements ETF
4.57%
ARK Genomic Revolution ETF
4.41%
ROBO Global Healthcare Technology & Innovation ETF
2.33%
Invesco Dorsey Wright Industrials Momentum ETF
1.77%
First Trust Nasdaq Lux Digi Health Solutions ETF
1.19%
Even Herd Long Short ETF
0.94%
First Trust Small Cap Growth AlphaDEX Fund
0.79%
Invesco NASDAQ Future Gen 200 ETF
0.71%
Invesco Dorsey Wright SmallCap Momentum ETF
0.65%
iShares Micro-Cap ETF
0.5%
View more
Franklin Genomic Advancements ETF
Proportion4.57%
ARK Genomic Revolution ETF
Proportion4.41%
ROBO Global Healthcare Technology & Innovation ETF
Proportion2.33%
Invesco Dorsey Wright Industrials Momentum ETF
Proportion1.77%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion1.19%
Even Herd Long Short ETF
Proportion0.94%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.79%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.71%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.65%
iShares Micro-Cap ETF
Proportion0.5%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Adaptive Biotechnologies Corp?
The top five shareholders of Adaptive Biotechnologies Corp are:
Viking Global Investors LP holds 29.99M shares, accounting for 19.65% of the total shares.
The Vanguard Group, Inc. holds 11.25M shares, accounting for 7.37% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.91M shares, accounting for 7.15% of the total shares.
Columbia Threadneedle Investments (US) holds 5.78M shares, accounting for 3.79% of the total shares.
Amova Asset Management Co., Ltd. holds 3.65M shares, accounting for 2.39% of the total shares.
Viking Global Investors LP holds 29.99M shares, accounting for 19.65% of the total shares.
The Vanguard Group, Inc. holds 11.25M shares, accounting for 7.37% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.91M shares, accounting for 7.15% of the total shares.
Columbia Threadneedle Investments (US) holds 5.78M shares, accounting for 3.79% of the total shares.
Amova Asset Management Co., Ltd. holds 3.65M shares, accounting for 2.39% of the total shares.
What are the top three shareholder types of Adaptive Biotechnologies Corp?
The top three shareholder types of Adaptive Biotechnologies Corp are:
Viking Global Investors LP
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Viking Global Investors LP
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Adaptive Biotechnologies Corp (ADPT)?
As of 2025Q4, 513 institutions hold shares of Adaptive Biotechnologies Corp, with a combined market value of approximately 148.08M, accounting for 97.00% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -8.05%.
What is the biggest source of revenue for Adaptive Biotechnologies Corp?
In FY2025Q3, the MRD revenue business generated the highest revenue for Adaptive Biotechnologies Corp, amounting to 56.79M and accounting for 60.43% of total revenue.
